News

With NIH grant, Springbok Analytics takes on rotator cuff injuries

Springbok Analytics, a Charlottesville medical data company that creates 3D models from X-rays and MRIs, has received a $1.7 million government grant to develop a commercially viable algorithm that can detect and diagnose shoulder injuriesThe grant, announced Tuesday, comes from the National Science Foundation’s Small Business Innovation Research grant program. It follows a $51,409 grant the company received from the NIH in 2022 to start its R&D on the project.

Springbok will work with research partners at the University of Virginia, University of Wisconsin and the San Antonio Orthopedic Group on AI technology to provide “a more accurate and objective scoring system” for evaluating rotator cuff muscles and to gauge the prospects of patient surgeries.

Lara Riem, Springbok’s director of AI and data science, said in a statement the company created an “extensive digital database” of healthy and injured rotator cuffs through phase I of the project. She said that database helped it establish key metrics evaluating muscles that can be “derived precisely and automatically, at scale” from magnetic resonance images.

Springbok said completion of a phase II trial of the new analysis system will allow it to apply for commercial clearance from the Food and Drug Administration.

“Our ultimate goal at Springbok Analytics is to become the standard for how we understand human musculature and improve clinical diagnosis, injury management and human performance through innovative, AI-based technologies,” co-founder and Chief Science Officer Silvia Blemker said in a statement.

Springbok’s 3D MRI imaging services are used by teams across the NFL, NBA, MLB, NHL, Premier League and NCAA. Last April, it closed an oversubscribed $3 million seed round led by Transition Equity Partners that included participation from the NHL’s Chicago Blackhawks.

Read more here.

Recent News

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan

10/20/2025

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment beginning in 2025 to